Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Silvio Danese
Observed name:
S Danese
Institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
Observed institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
ORCID:
0000-0001-7341-1351
Observed ORCID:
0000-0001-7341-1351
OpenAlex ID:
A5123520804
OP30 Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease
2026
·
S Danese
, F Magro
, et al.
·
Journal of Crohn s and Colitis
·
4
Tools and advanced imaging technologies for assessing intestinal epithelial barrier integrity: a systematic review
2026
·
Sophie Vieujean
, Raja Atreya
, et al.
·
American Journal of Physiology-Gastrointestinal and Liver Physiology
·
3
P1007 Evaluation of transmural healing in patients with moderately to severely active Crohn’s disease shows early efficacy of vedolizumab: VECTORS week 14 interim analysis
2026
·
V Jairath
, S K Vuyyuru
, et al.
·
Journal of Crohn s and Colitis
·
3
O85 Guselkumab for perianal fistulizing crohn’s disease: week 24 results from the Phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study
2026
·
Ailsa Hart
, Laurent Peyrin-Biroulet
, et al.
·
Gut
·
2
PDF
P734 A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn’s disease prognosis - a prospective study
2023
·
F Magro
, M M Estevinho
, et al.
·
Journal of Crohn s and Colitis
·
2
PDF
P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension
2021
·
D S Rowbotham
, E J Scherl
, et al.
·
Journal of Crohn s and Colitis
·
2
Risk of avoidant/restrictive food intake disorders in patients with inflammatory bowel disease: a matched cross-sectional case-control study
2026
·
Olga Maria Nardone
, Ferdinando D’Amico
, et al.
·
Journal of Crohn s and Colitis
·
1
DOP062 Efficacy of etrasimod in biologic/Janus kinase inhibitor-naïve patients with mildly to moderately active Ulcerative Colitis: results from the GLADIATOR trial
2026
·
A Yarur
, M C Dubinsky
, et al.
·
Journal of Crohn s and Colitis
·
1
P0925 Pharmacokinetics and exposure-response relationships of guselkumab intravenous or subcutaneous induction in participants with Ulcerative Colitis
2026
·
L Peyrin-Biroulet
, Z Xu
, et al.
·
Journal of Crohn s and Colitis
·
1
P0593 Impact of up to 3 years of continuous etrasimod treatment: Long-term efficacy results from the ELEVATE UC open-label extension
2026
·
B E Sands
, M C Dubinsky
, et al.
·
Journal of Crohn s and Colitis
·
1
P0712 Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials
2026
·
U Seidler
, S Danese
, et al.
·
Journal of Crohn s and Colitis
·
1
DOP001 Extraintestinal manifestations in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GALAXI 2 & 3 studies
2026
·
S Danese
, T Hisamatsu
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
P1075 Etrasimod for the treatment of Ulcerative Colitis: up to 5 years of safety data from the global clinical programme
2026
·
D T Rubin
, M Regueiro
, et al.
·
Journal of Crohn s and Colitis
·
1
P0978 SKYLINE-UC: The First Platform Study in Ulcerative Colitis Assessing Efficacy and Safety of Three Long-Acting Antibodies Administered as Single Agents and in Combinations
2026
·
S Danese
, V Jairath
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
P0596 Efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease who had maintenance dose adjustment: Results from the phase 3 GALAXI 2 & 3 long-term extension
2026
·
R Panaccione
, T Hisamatsu
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
DOP031 Analysis of Long-Term Safety and Efficacy of Risankizumab in Patients With Moderate-to-Severe Crohn’s Disease: 3-Year Results From the SEQUENCE Study
2026
·
L Peyrin-Biroulet
, R Atreya
, et al.
·
Journal of Crohn s and Colitis
·
1
P0924 Long-term etrasimod efficacy in patients with Ulcerative Colitis stratified by prior biologic/JAKi experience: 2-year outcomes from ELEVATE UC OLE
2026
·
B E Sands
, M C Dubinsky
, et al.
·
Journal of Crohn s and Colitis
·
1
P0423 Patient-Physician mismatch in therapeutic targets for advanced therapy in inflammatory bowel disease patients: the PROMISE study
2026
·
G Fiorino
, M Salice
, et al.
·
Journal of Crohn s and Colitis
·
1
PDF
P0401 Intestinal Ultrasound Accurately Detects Endoscopic Activity in Pediatric Ulcerative Colitis: A Prospective Bicentric Validation Study
2026
·
S Massironi
, G Mulinacci
, et al.
·
Journal of Crohn s and Colitis
·
1
Efficacy of obefazimod in ABTECT phase 3 induction trials: results of 8-week therapy in subsets of patients with and without prior inadequate response to advanced therapies
2026
·
R Atreya
, S Danese
, et al.
·
Zeitschrift für Gastroenterologie
Efficacy of intravenous and subcutaneous guselkumab induction by weight and body mass index in patients with Crohn’s disease: Results from the phase 3 GALAXI and GRAVITI studies
2026
·
E Schnoy
, P Deepak
, et al.
·
Zeitschrift für Gastroenterologie
Efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis: results from two, phase 3, randomised, double-blind, placebo-controlled, 8-week induction trials (ABTECT 1 & 2)
2026
·
B Siegmund
, B E Sands
, et al.
·
Zeitschrift für Gastroenterologie
Analysis of long-term safety and efficacy of risankizumab in patients with moderate-to-severe Crohn’s Disease: 3-year results from the SEQUENCE study
2026
·
L Peyrin-Biroulet
, R Atreya
, et al.
·
Zeitschrift für Gastroenterologie
Impact of up to 3 years of continuous etrasimod treatment: long-term efficacy results from the ELEVATE UC open-label extension
2026
·
B E Sands
, M C Dubinsky
, et al.
·
Zeitschrift für Gastroenterologie
Mirikizumab demonstrates consistent and sustained disease clearance at four years of treatment in patients with moderately to severely active ulcerative colitis
2026
·
F Magro
, S Danese
, et al.
·
Zeitschrift für Gastroenterologie
Show more works
View as search
Works count:
63
Citation count:
29
H-index:
3
I10-index:
Year
Topic
Type